Concepts (193)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiology | 5 | 2022 | 169 | 1.860 |
Why?
|
| Myocardial Infarction | 3 | 2022 | 917 | 1.270 |
Why?
|
| Troponin | 3 | 2022 | 39 | 0.970 |
Why?
|
| Hypertension | 3 | 2022 | 609 | 0.880 |
Why?
|
| Fellowships and Scholarships | 3 | 2023 | 106 | 0.830 |
Why?
|
| Heart Failure | 3 | 2024 | 940 | 0.730 |
Why?
|
| Parental Leave | 1 | 2021 | 10 | 0.700 |
Why?
|
| Policy Making | 1 | 2021 | 47 | 0.690 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 136 | 0.660 |
Why?
|
| Acute Coronary Syndrome | 2 | 2022 | 252 | 0.640 |
Why?
|
| Vascular Stiffness | 3 | 2024 | 17 | 0.620 |
Why?
|
| Cardiovascular Diseases | 5 | 2025 | 859 | 0.590 |
Why?
|
| Defibrillators, Implantable | 1 | 2022 | 273 | 0.570 |
Why?
|
| Cardiologists | 2 | 2022 | 28 | 0.550 |
Why?
|
| Patient Readmission | 2 | 2021 | 444 | 0.550 |
Why?
|
| Stroke Volume | 3 | 2024 | 338 | 0.530 |
Why?
|
| Aortic Valve Stenosis | 2 | 2025 | 190 | 0.470 |
Why?
|
| Humans | 34 | 2025 | 64729 | 0.420 |
Why?
|
| Antihypertensive Agents | 3 | 2022 | 178 | 0.410 |
Why?
|
| Risk Assessment | 3 | 2022 | 2086 | 0.410 |
Why?
|
| Cardiotoxicity | 2 | 2019 | 17 | 0.390 |
Why?
|
| Hypotension, Orthostatic | 1 | 2022 | 27 | 0.370 |
Why?
|
| Aortic Valve | 2 | 2025 | 181 | 0.370 |
Why?
|
| Awards and Prizes | 1 | 2022 | 33 | 0.360 |
Why?
|
| Glucosides | 1 | 2021 | 15 | 0.350 |
Why?
|
| Pacemaker, Artificial | 1 | 2022 | 50 | 0.340 |
Why?
|
| Benzhydryl Compounds | 1 | 2021 | 61 | 0.330 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2021 | 40 | 0.330 |
Why?
|
| Heart Valve Prosthesis | 1 | 2022 | 106 | 0.320 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2022 | 110 | 0.310 |
Why?
|
| Fluorouracil | 1 | 2019 | 67 | 0.310 |
Why?
|
| Anthracyclines | 1 | 2019 | 11 | 0.300 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 37 | 0.290 |
Why?
|
| Biomarkers | 4 | 2025 | 1465 | 0.290 |
Why?
|
| United States | 7 | 2022 | 8041 | 0.290 |
Why?
|
| Adrenocortical Adenoma | 1 | 2018 | 2 | 0.290 |
Why?
|
| Aspirin | 2 | 2020 | 171 | 0.290 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2018 | 4 | 0.290 |
Why?
|
| Aldosterone | 1 | 2018 | 18 | 0.280 |
Why?
|
| Hyperaldosteronism | 1 | 2018 | 9 | 0.280 |
Why?
|
| Ultraviolet Rays | 2 | 2016 | 146 | 0.280 |
Why?
|
| Aged | 11 | 2024 | 14834 | 0.280 |
Why?
|
| Ventricular Function, Left | 3 | 2024 | 275 | 0.270 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 232 | 0.270 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 160 | 0.270 |
Why?
|
| Clinical Clerkship | 1 | 2018 | 91 | 0.260 |
Why?
|
| Behavior, Addictive | 1 | 2018 | 75 | 0.260 |
Why?
|
| Pulse Wave Analysis | 2 | 2024 | 15 | 0.260 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2022 | 63 | 0.260 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2016 | 4 | 0.250 |
Why?
|
| Skin Aging | 1 | 2016 | 11 | 0.250 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2024 | 114 | 0.250 |
Why?
|
| Referral and Consultation | 2 | 2020 | 427 | 0.240 |
Why?
|
| Male | 15 | 2024 | 30790 | 0.240 |
Why?
|
| Cost-Benefit Analysis | 2 | 2022 | 315 | 0.240 |
Why?
|
| Radiation Exposure | 1 | 2016 | 24 | 0.230 |
Why?
|
| Blood Pressure | 2 | 2022 | 525 | 0.230 |
Why?
|
| Female | 15 | 2024 | 33739 | 0.230 |
Why?
|
| Pain | 1 | 2018 | 398 | 0.230 |
Why?
|
| Rosacea | 1 | 2015 | 1 | 0.230 |
Why?
|
| Lipoprotein(a) | 1 | 2025 | 8 | 0.230 |
Why?
|
| Students, Medical | 1 | 2018 | 265 | 0.220 |
Why?
|
| Global Health | 2 | 2022 | 180 | 0.220 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2024 | 168 | 0.220 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 462 | 0.210 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 239 | 0.210 |
Why?
|
| Middle Aged | 11 | 2024 | 18106 | 0.210 |
Why?
|
| Asymptomatic Diseases | 1 | 2024 | 50 | 0.210 |
Why?
|
| Telemedicine | 2 | 2019 | 357 | 0.210 |
Why?
|
| Kidney | 1 | 2016 | 451 | 0.210 |
Why?
|
| Ventricular Remodeling | 1 | 2024 | 90 | 0.200 |
Why?
|
| Retrospective Studies | 5 | 2021 | 6803 | 0.200 |
Why?
|
| Skin | 1 | 2016 | 414 | 0.200 |
Why?
|
| Transcriptome | 1 | 2016 | 396 | 0.190 |
Why?
|
| Clinical Competence | 1 | 2018 | 723 | 0.190 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 792 | 0.190 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 358 | 0.190 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 789 | 0.190 |
Why?
|
| Exercise Test | 1 | 2024 | 256 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 1656 | 0.180 |
Why?
|
| Electronics | 1 | 2022 | 32 | 0.180 |
Why?
|
| Chest Pain | 1 | 2022 | 85 | 0.180 |
Why?
|
| American Heart Association | 1 | 2022 | 128 | 0.180 |
Why?
|
| Reimbursement Mechanisms | 1 | 2021 | 41 | 0.180 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 989 | 0.170 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1135 | 0.170 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 403 | 0.170 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 5562 | 0.160 |
Why?
|
| Embolectomy | 1 | 2020 | 15 | 0.160 |
Why?
|
| Medicare | 2 | 2021 | 615 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2021 | 146 | 0.160 |
Why?
|
| Physicians, Women | 1 | 2019 | 40 | 0.150 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2019 | 29 | 0.150 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 66 | 0.150 |
Why?
|
| Cell Phone | 1 | 2019 | 42 | 0.140 |
Why?
|
| Thrombolytic Therapy | 1 | 2020 | 195 | 0.140 |
Why?
|
| Neoplasms | 1 | 2019 | 1357 | 0.140 |
Why?
|
| Heart Diseases | 1 | 2021 | 222 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2020 | 278 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2021 | 1001 | 0.140 |
Why?
|
| Insurance, Health | 1 | 2019 | 151 | 0.140 |
Why?
|
| Risk Factors | 4 | 2024 | 5393 | 0.130 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 194 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2020 | 335 | 0.130 |
Why?
|
| Exercise | 1 | 2024 | 959 | 0.130 |
Why?
|
| Adult | 7 | 2024 | 17230 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 801 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2020 | 872 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2023 | 810 | 0.120 |
Why?
|
| Incidence | 1 | 2019 | 1409 | 0.110 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 2753 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2024 | 1104 | 0.100 |
Why?
|
| Sex Factors | 3 | 2021 | 987 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 1689 | 0.090 |
Why?
|
| Phenotype | 2 | 2016 | 1231 | 0.090 |
Why?
|
| Morbidity | 1 | 2022 | 110 | 0.090 |
Why?
|
| Markov Chains | 1 | 2021 | 36 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 2680 | 0.080 |
Why?
|
| Capecitabine | 1 | 2019 | 14 | 0.080 |
Why?
|
| Survival Rate | 1 | 2022 | 847 | 0.080 |
Why?
|
| Protective Factors | 1 | 2019 | 33 | 0.070 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 39 | 0.070 |
Why?
|
| Hyaluronan Synthases | 1 | 2016 | 2 | 0.060 |
Why?
|
| Glucuronosyltransferase | 1 | 2016 | 9 | 0.060 |
Why?
|
| Gene Ontology | 1 | 2016 | 37 | 0.060 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 36 | 0.060 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2018 | 158 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2022 | 1555 | 0.060 |
Why?
|
| Plasma Cells | 1 | 2016 | 52 | 0.060 |
Why?
|
| Rituximab | 1 | 2016 | 88 | 0.060 |
Why?
|
| Young Adult | 2 | 2016 | 4771 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2016 | 260 | 0.060 |
Why?
|
| RNA, Untranslated | 1 | 2016 | 105 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 543 | 0.060 |
Why?
|
| Adolescent | 2 | 2016 | 6291 | 0.060 |
Why?
|
| Pregnancy | 1 | 2022 | 2363 | 0.060 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2015 | 2 | 0.060 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2015 | 4 | 0.060 |
Why?
|
| HLA-DRB1 Chains | 1 | 2015 | 16 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 461 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2021 | 2603 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 179 | 0.060 |
Why?
|
| Quality Control | 1 | 2015 | 78 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2016 | 497 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 522 | 0.050 |
Why?
|
| Mississippi | 1 | 2024 | 15 | 0.050 |
Why?
|
| Prognosis | 1 | 2019 | 1770 | 0.050 |
Why?
|
| Aorta, Thoracic | 1 | 2024 | 80 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2015 | 182 | 0.050 |
Why?
|
| Curriculum | 1 | 2018 | 603 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2018 | 740 | 0.050 |
Why?
|
| Alleles | 1 | 2015 | 452 | 0.050 |
Why?
|
| Genotype | 1 | 2015 | 670 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 897 | 0.050 |
Why?
|
| Diastole | 1 | 2022 | 91 | 0.050 |
Why?
|
| Internet | 1 | 2016 | 465 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 506 | 0.050 |
Why?
|
| Smoking | 1 | 2016 | 860 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 733 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2021 | 121 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2023 | 350 | 0.040 |
Why?
|
| Vena Cava Filters | 1 | 2020 | 23 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 58 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2020 | 69 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2020 | 163 | 0.040 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2020 | 50 | 0.040 |
Why?
|
| Erythrocyte Transfusion | 1 | 2020 | 77 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2021 | 177 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 250 | 0.040 |
Why?
|
| Diabetic Angiopathies | 1 | 2019 | 29 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 222 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 112 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2016 | 1549 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2019 | 98 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2020 | 266 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 879 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2020 | 416 | 0.030 |
Why?
|
| Inflammation | 1 | 2015 | 1185 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1633 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2019 | 136 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 745 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 1432 | 0.030 |
Why?
|
| Echocardiography | 1 | 2020 | 509 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1268 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 404 | 0.030 |
Why?
|
| Length of Stay | 1 | 2020 | 822 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 768 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 459 | 0.030 |
Why?
|
| Medicaid | 1 | 2019 | 367 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2016 | 5758 | 0.030 |
Why?
|
| Health Promotion | 1 | 2019 | 512 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 1122 | 0.020 |
Why?
|
| Animals | 1 | 2019 | 21292 | 0.020 |
Why?
|